These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

987 related articles for article (PubMed ID: 21930769)

  • 1. Type I interferon is selectively required by dendritic cells for immune rejection of tumors.
    Diamond MS; Kinder M; Matsushita H; Mashayekhi M; Dunn GP; Archambault JM; Lee H; Arthur CD; White JM; Kalinke U; Murphy KM; Schreiber RD
    J Exp Med; 2011 Sep; 208(10):1989-2003. PubMed ID: 21930769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant.
    Longhi MP; Trumpfheller C; Idoyaga J; Caskey M; Matos I; Kluger C; Salazar AM; Colonna M; Steinman RM
    J Exp Med; 2009 Jul; 206(7):1589-602. PubMed ID: 19564349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I IFN Sensing by cDCs and CD4
    Shirley JL; Keeler GD; Sherman A; Zolotukhin I; Markusic DM; Hoffman BE; Morel LM; Wallet MA; Terhorst C; Herzog RW
    Mol Ther; 2020 Mar; 28(3):758-770. PubMed ID: 31780366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma.
    Kamath AT; Sheasby CE; Tough DF
    J Immunol; 2005 Jan; 174(2):767-76. PubMed ID: 15634897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells.
    Fuertes MB; Kacha AK; Kline J; Woo SR; Kranz DM; Murphy KM; Gajewski TF
    J Exp Med; 2011 Sep; 208(10):2005-16. PubMed ID: 21930765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes.
    Lu C; Klement JD; Ibrahim ML; Xiao W; Redd PS; Nayak-Kapoor A; Zhou G; Liu K
    J Immunother Cancer; 2019 Jun; 7(1):157. PubMed ID: 31228946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1.
    Crouse J; Bedenikovic G; Wiesel M; Ibberson M; Xenarios I; Von Laer D; Kalinke U; Vivier E; Jonjic S; Oxenius A
    Immunity; 2014 Jun; 40(6):961-73. PubMed ID: 24909889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
    Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W
    J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I IFN-induced, NKT cell-mediated negative control of CD8 T cell priming by dendritic cells.
    Bochtler P; Kröger A; Schirmbeck R; Reimann J
    J Immunol; 2008 Aug; 181(3):1633-43. PubMed ID: 18641299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
    Deng L; Liang H; Xu M; Yang X; Burnette B; Arina A; Li XD; Mauceri H; Beckett M; Darga T; Huang X; Gajewski TF; Chen ZJ; Fu YX; Weichselbaum RR
    Immunity; 2014 Nov; 41(5):843-52. PubMed ID: 25517616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions.
    Willemen Y; Van den Bergh JM; Lion E; Anguille S; Roelandts VA; Van Acker HH; Heynderickx SD; Stein BM; Peeters M; Figdor CG; Van Tendeloo VF; de Vries IJ; Adema GJ; Berneman ZN; Smits EL
    Cancer Immunol Immunother; 2015 Jul; 64(7):831-42. PubMed ID: 25863943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A marked reduction in priming of cytotoxic CD8+ T cells mediated by stress-induced glucocorticoids involves multiple deficiencies in cross-presentation by dendritic cells.
    Hunzeker JT; Elftman MD; Mellinger JC; Princiotta MF; Bonneau RH; Truckenmiller ME; Norbury CC
    J Immunol; 2011 Jan; 186(1):183-94. PubMed ID: 21098225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cell therapy with interferon-alpha synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model.
    Ishii S; Hiroishi K; Eguchi J; Hiraide A; Imawari M
    Gene Ther; 2006 Jan; 13(1):78-87. PubMed ID: 16107857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TLR3-Mediated CD8+ Dendritic Cell Activation Is Coupled with Establishment of a Cell-Intrinsic Antiviral State.
    Széles L; Meissner F; Dunand-Sauthier I; Thelemann C; Hersch M; Singovski S; Haller S; Gobet F; Fuertes Marraco SA; Mann M; Garcin D; Acha-Orbea H; Reith W
    J Immunol; 2015 Aug; 195(3):1025-33. PubMed ID: 26101320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activating immunity in the liver. II. IFN-beta attenuates NK cell-dependent liver injury triggered by liver NKT cell activation.
    Trobonjaca Z; Kröger A; Stober D; Leithäuser F; Möller P; Hauser H; Schirmbeck R; Reimann J
    J Immunol; 2002 Apr; 168(8):3763-70. PubMed ID: 11937527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.
    Fujii S; Shimizu K; Smith C; Bonifaz L; Steinman RM
    J Exp Med; 2003 Jul; 198(2):267-79. PubMed ID: 12874260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma.
    Hömberg N; Adam C; Riedel T; Brenner C; Flatley A; Röcken M; Mocikat R
    Int J Cancer; 2014 Dec; 135(12):2825-33. PubMed ID: 24771135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response.
    Xia X; Mai J; Xu R; Perez JET; Guevara ML; Shen Q; Mu C; Tung HY; Corry DB; Evans SE; Liu X; Ferrari M; Zhang Z; Li XC; Wang RF; Shen H
    Cell Rep; 2015 May; 11(6):957-966. PubMed ID: 25937283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
    Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
    Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.